Delporte J P, Rorive G
Service de Pharmacie, Université de Liège.
Rev Med Liege. 1998 May;53(5):259-64.
Hypertension affects a large proportion of the adult population. Subsequently any change in treatment strategy may have a drastic impact on health expenditure especially when one decides to decrease the limits of arterial pressure beyond which a treatment is started. Results of pharmaco-economic studies are often controversial because they are mainly based on an evaluation of short-term absolute risks, maybe underestimating the benefit of a treatment in younger population with mild to moderate hypertension. All groups of antihypertensive drugs are able to reduce the blood pressure and most of them can induce a light improvement of patient quality of life. Diuretics and beta-blockers have a lower cost/effectiveness ratio. ACE inhibitors and calcium antagonists may be preferred when other drugs are badly tolerated or when some other morbidities affect the patient.
高血压影响着很大一部分成年人口。因此，治疗策略的任何改变都可能对医疗支出产生巨大影响，尤其是当人们决定降低开始治疗的动脉血压阈值时。药物经济学研究的结果往往存在争议，因为它们主要基于对短期绝对风险的评估，可能低估了治疗对轻度至中度高血压年轻人群的益处。所有种类的抗高血压药物都能够降低血压，并且大多数药物都能在一定程度上改善患者的生活质量。利尿剂和β受体阻滞剂的成本效益比更低。当患者对其他药物耐受性差或患有其他疾病时，可能更倾向于使用ACE抑制剂和钙拮抗剂。
